drugset / Trial / NCT03688711

Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM

NCT03688711

Phase 3 Completed 45 enrolled Zealand Pharma
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A randomized, double-blind, parallel-group trial to confirm the clinical efficacy and safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 1 diabetes mellitus (T1DM) compared to placebo

Timeline

Start
2018-11-01
Primary completion
2019-03-11
Completion
2019-03-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Dasiglucagon Peptide 0.6 mg Subcutaneous